Amgen’s New Enbrel Patent May Undercut Health Care Plan

Wednesday, November 23, 2011 - 10:10 in Health & Medicine

The extra patent protection of the profitable drug Enbrel, a rheumatoid arthritis and psoriasis treatment, could keep a cheaper version off the market until 2028.

Read the whole article on NY Times Health

More from NY Times Health

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net